Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3046)
All Articles published online
|
Apr 28, 2007 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study. World J Gastroenterol 2007; 13(16): 2328-2332 [PMID: 17511032 DOI: 10.3748/wjg.v13.i16.2328] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i16/2328.htm |
| Number | Citing Articles |
| 1 |
F. Grimpen, P. Pavli. Advances in the management of inflammatory bowel disease. Internal Medicine Journal 2010; 40(4): 258 doi: 10.1111/j.1445-5994.2010.02163.x
|
| 2 |
A. L. Hart, S. C. Ng. Review article: the optimal medical management of acute severe ulcerative colitis. Alimentary Pharmacology & Therapeutics 2010; 32(5): 615 doi: 10.1111/j.1365-2036.2010.04392.x
|
| 3 |
Oliver Brain, Simon PL Travis. Therapy of ulcerative colitis: state of the art. Current Opinion in Gastroenterology 2008; 24(4): 469 doi: 10.1097/MOG.0b013e3282ff0dd5
|
| 4 |
Vandana Midha, Ramit Mahajan, Varun Mehta, Vikram Narang, Arshdeep Singh, Kirandeep Kaur, Ajit Sood. Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis. Intestinal Research 2018; 16(1): 83 doi: 10.5217/ir.2018.16.1.83
|
| 5 |
Catherine Reenaers, Edouard Louis, Jacques Belaiche. Review: Current directions of biologic therapies in inflammatory bowel disease. Therapeutic Advances in Gastroenterology 2010; 3(2): 99 doi: 10.1177/1756283X09356872
|
| 6 |
Jean Bousquet, Raphael Chiron, Marc Humbert. Biologics in asthma: difficulties and drawbacks. Expert Opinion on Biological Therapy 2008; 8(12): 1921 doi: 10.1517/14712590802496928
|
| 7 |
P. Marteau, X. Dray. IBD 2007 — Achievements in Research and Clinical Practice. Falk Symposium 2008; 159: 208 doi: 10.1007/978-1-4020-6987-1_20
|
| 8 |
Claudia Fuxman, Beatriz Sicilia, María Eugenia Linares, Santiago García-López, Ramiro González Sueyro, Yago González-Lamac, Yamile Zabana, Joaquín Hinojosa, Manuel Barreiro-de Acosta, Domingo Balderramo, Deborah Balfour, Maricel Bellicoso, Pamela Daffra, Daniela Morelli, Marina Orsi, Astrid Rausch, Orlando Ruffinengo, Martín Toro, Alicia Sambuelli, Abel Novillo, Fernando Gomollón, Juan Andrés De Paula. Guía GADECCU 2022 para el tratamiento de la colitis ulcerosa. Adaptación y actualización de la Guía GETECCU 2020. Gastroenterología y Hepatología 2023; 46: S1 doi: 10.1016/j.gastrohep.2023.01.009
|
| 9 |
Luca Pastorelli, Theresa T Pizarro, Fabio Cominelli, Maurizio Vecchi. Emerging drugs for the treatment of ulcerative colitis. Expert Opinion on Emerging Drugs 2009; 14(3): 505 doi: 10.1517/14728210903146882
|
| 10 |
Joanne E. Brady, Marni Stott-Miller, George Mu, Sue Perera. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease. Clinical Therapeutics 2018; 40(9): 1509 doi: 10.1016/j.clinthera.2018.07.013
|
| 11 |
Mohamed Attauabi, Emilie Kristine Dahl, Johan Burisch, John Gubatan, Ole Haagen Nielsen, Jakob Benedict Seidelin. Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. eClinicalMedicine 2023; 57: 101866 doi: 10.1016/j.eclinm.2023.101866
|
| 12 |
Oliver Brain, Simon PL Travis. Therapy of ulcerative colitis: state of the art. Current Opinion in Internal Medicine 2008; 7(5): 477 doi: 10.1097/MCI.0b013e3283154e13
|
| 13 |
Naga K.R. Ghattamaneni, Sunil K. Panchal, Lindsay Brown. Nutraceuticals in rodent models as potential treatments for human Inflammatory Bowel Disease. Pharmacological Research 2018; 132: 99 doi: 10.1016/j.phrs.2018.04.015
|
| 14 |
Sara Renna, Mario Cottone, Ambrogio Orlando. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World Journal of Gastroenterology 2014; 20(29): 9675-9690 doi: 10.3748/wjg.v20.i29.9675
|
| 15 |
Manuel Barreiro-de Acosta, Orlando García-Bosch, Jordi Gordillo, Miriam Mañosa, Luis Menchén, Raquel Souto, Ignacio Marin-Jimenez. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab. European Journal of Gastroenterology & Hepatology 2012; 24(7): 756 doi: 10.1097/MEG.0b013e3283525a7b
|
| 16 |
Silvio Danese. Adalimumab in ulcerative colitis: Ready for prime time. Digestive and Liver Disease 2013; 45(1): 8 doi: 10.1016/j.dld.2012.05.021
|
| 17 |
Axel Dignass, James O. Lindsay, Andreas Sturm, Alastair Windsor, Jean-Frederic Colombel, Mathieu Allez, Gert D'Haens, André D'Hoore, Gerassimos Mantzaris, Gottfried Novacek, Tom Öresland, Walter Reinisch, Miquel Sans, Eduard Stange, Severine Vermeire, Simon Travis, Gert Van Assche. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. Journal of Crohn's and Colitis 2012; 6(10): 991 doi: 10.1016/j.crohns.2012.09.002
|
| 18 |
N. Gies, K. I. Kroeker, K. Wong, R. N. Fedorak. Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohort. Alimentary Pharmacology & Therapeutics 2010; 32(4): 522 doi: 10.1111/j.1365-2036.2010.04380.x
|
| 19 |
Orlando García-Bosch, Javier P. Gisbert, Àlex Cañas-Ventura, Olga Merino, José L. Cabriada, Valle García-Sánchez, Ana Gutiérrez, Pilar Nos, Mireia Peñalva, Joaquin Hinojosa, Esther García-Planella, Fernando Muñoz, Xavier Calvet, Julián Panés. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. Journal of Crohn's and Colitis 2013; 7(9): 717 doi: 10.1016/j.crohns.2012.10.004
|
| 20 |
Miles P. Sparrow. Adalimumab in ulcerative colitis – efficacy, safety and optimization in the era of treat-to target. Expert Opinion on Biological Therapy 2017; 17(5): 613 doi: 10.1080/14712598.2017.1309390
|
| 21 |
Beatriz Sicilia, Santiago García-López, Yago González-Lama, Yamile Zabana, Joaquín Hinojosa, Fernando Gomollón. Guía GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodología GRADE. Gastroenterología y Hepatología 2020; 43: 1 doi: 10.1016/j.gastrohep.2020.07.001
|
| 22 |
L. Peyrin-Biroulet. Anti-TNF et maladie de Crohn. Gastroentérologie Clinique et Biologique 2008; 32(5): 478 doi: 10.1016/j.gcb.2008.03.004
|
| 23 |
Harpreet Singh, Liam Wilson, Tom Tencer, Jinender Kumar. Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis. ClinicoEconomics and Outcomes Research 2023; : 125 doi: 10.2147/CEOR.S391413
|
| 24 |
Manuel Barreiro-de Acosta, Aurelio Lorenzo, Juan Enrique Dominguez-Muñoz. Adalimumab in ulcerative colitis: Two cases of mucosal healing and clinical response at two years. World Journal of Gastroenterology 2009; 15(30): 3814-3816 doi: 10.3748/wjg.15.3814
|
| 25 |
Gionata Fiorino, Laurent Peyrin-Biroulet, Alessandro Repici, Alberto Malesci, Silvio Danese. Adalimumab in ulcerative colitis: hypes and hopes. Expert Opinion on Biological Therapy 2011; 11(1): 109 doi: 10.1517/14712598.2011.541435
|
| 26 |
M. Chaparro, J. Panés, V. García, O. Merino, P. Nos, E. Domènech, M. Peñalva, E. García-Planella, M. Esteve, J. Hinojosa, M. Andreu, F. Muñoz, A. Gutiérrez, J. L. Mendoza, J. Barrio, M. Barreiro-de, I. Vera, P. Vilar, J. L. Cabriada, M. A. Montoro, X. Aldeguer, C. Saro, J. P. Gisbert. Long-term durability of response to adalimumab in Crohnʼs disease. Inflammatory Bowel Diseases 2012; 18(4): 685 doi: 10.1002/ibd.21758
|
| 27 |
Onset of Ulcerative Colitis Under Treatment With Adalimumab. The American Journal of Gastroenterology 2008; 103(9): 2410 doi: 10.1111/j.1572-0241.2008.02010_11.x
|
| 28 |
G.‐T. HO, L. SMITH, S. AITKEN, H. M. LEE, T. TING, J. FENNELL, C. W. LEES, K. R. PALMER, I. D. PENMAN, A. G. SHAND, I. D. ARNOTT, J. SATSANGI. The use of adalimumab in the management of refractory Crohn’s disease. Alimentary Pharmacology & Therapeutics 2008; 27(4): 308 doi: 10.1111/j.1365-2036.2007.03583.x
|
| 29 |
S. C. NG, M. A. KAMM. Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. Alimentary Pharmacology & Therapeutics 2008; 28(7): 815 doi: 10.1111/j.1365-2036.2008.03800.x
|
| 30 |
Jin-shan Feng, Jin-yu Li, Xiu-yan Chen, Zheng Yang, Shang-hai Li. Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-Analysis. Gastroenterology Research and Practice 2017; 2017: 1 doi: 10.1155/2017/7896160
|
| 31 |
Florian Grimpen, Paul Pavli. Inflammatory Bowel Disease in Older People. Journal of Pharmacy Practice and Research 2008; 38(3): 234 doi: 10.1002/j.2055-2335.2008.tb00847.x
|
| 32 |
Zong Mei Zhang, Wei Li, Xue Liang Jiang. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials. Gut and Liver 2016; 10(2): 262 doi: 10.5009/gnl15042
|
| 33 |
Rachel Archer, Paul Tappenden, Shijie Ren, Marrissa Martyn-St James, Rebecca Harvey, Hasan Basarir, John Stevens, Christopher Carroll, Anna Cantrell, Alan Lobo, Sami Hoque. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technology Assessment 2016; 20(39): 1 doi: 10.3310/hta20390
|
| 34 |
Walter Reinisch. Crohn's Disease and Ulcerative Colitis. 2012; : 495 doi: 10.1007/978-1-4614-0998-4_41
|
| 35 |
Siew C. Ng, Michael A. Kamm. Therapeutic strategies for the management of ulcerative colitis. Inflammatory Bowel Diseases 2009; 15(6): 935 doi: 10.1002/ibd.20797
|
| 36 |
Abhishek Bhurwal, Carlos D Minacapelli, Anish Patel, Hemant Mutneja, Akshay Goel, Ishani Shah, Vikas Bansal, Bhaumik Brahmbhatt, Kiron M Das. Evaluation of a U.S. National Cohort to Determine Utilization in Colectomy Rates for Ulcerative Colitis Among Ethnicities. Inflammatory Bowel Diseases 2022; 28(1): 54 doi: 10.1093/ibd/izab020
|
| 37 |
Mark A. Samaan, Preet Bagi, Niels Vande Casteele, Geert R. D’Haens, Barrett G. Levesque. An Update on Anti-TNF Agents in Ulcerative Colitis. Gastroenterology Clinics of North America 2014; 43(3): 479 doi: 10.1016/j.gtc.2014.05.006
|
| 38 |
Ming-Hsi Wang, Jean-Paul Achkar. Medical Therapy of Ulcerative Colitis. 2014; : 185 doi: 10.1007/978-1-4939-1677-1_16
|
| 39 |
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi. Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. Intestinal Research 2021; 19(4): 419 doi: 10.5217/ir.2020.00033
|
| 40 |
Sihem Ait‐Oudhia, Yi Ting (Kayla) Lien, Sumit Basu, Lawrence Lesko, Stephan Schmidt. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases. 2019; : 209 doi: 10.1002/9781119289234.ch10
|
| 41 |
Laura Yun, Stephen Hanauer. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2009; 3(3): 235 doi: 10.1586/egh.09.20
|
| 42 |
Ioannis E Koutroubakis. Recent advances in the management of distal ulcerative colitis. World Journal of Gastrointestinal Pharmacology and Therapeutics 2010; 1(2): 43-50 doi: 10.4292/wjgpt.v1.i2.43
|
| 43 |
William J. Sandborn, Gert van Assche, Walter Reinisch, Jean–Frederic Colombel, Geert D’Haens, Douglas C. Wolf, Martina Kron, Mary Beth Tighe, Andreas Lazar, Roopal B. Thakkar. Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2012; 142(2): 257 doi: 10.1053/j.gastro.2011.10.032
|
| 44 |
Subrata Ghosh, William J. Sandborn, Jean-Frederic Colombel, Brian G. Feagan, Remo Panaccione, Stephen Hanauer, Stefan Schreiber, Laurent Peyrin-Biroulet, Severine Vermeire, Samantha Eichner, Bidan Huang, Anne M. Robinson, Brandee Pappalardo. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 2016; 22(11): 2711 doi: 10.1097/MIB.0000000000000909
|
| 45 |
C. Taxonera, J. Estellés, I. Fernández-Blanco, O. Merino, I. Marín-Jiménez, M. Barreiro-de Acosta, C. Saro, V. García-Sánchez, E. Gento, G. Bastida, J. P. Gisbert, I. Vera, P. Martinez-Montiel, S. Garcia-Morán, M. C. Sánchez, J. L. Mendoza. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Alimentary Pharmacology & Therapeutics 2011; 33(3): 340 doi: 10.1111/j.1365-2036.2010.04531.x
|
| 46 |
Giovanni Monteleone, Francesco Pallone, Flavio Caprioli. Investigational cytokine-targeted therapies for ulcerative colitis. Expert Opinion on Investigational Drugs 2013; 22(9): 1123 doi: 10.1517/13543784.2013.813931
|
| 47 |
Walter Reinisch. Crohn's Disease and Ulcerative Colitis. 2017; : 435 doi: 10.1007/978-3-319-33703-6_43
|
| 48 |
Yuka Marutani, Tsutomu Mizoshita, Tomoya Sugiyama, Shozo Togawa, Takahito Katano, Tomonori Yamada, Yoshikazu Hirata, Yoshihide Kimura, Tomokatsu Miyaki, Yusuke Inoue, Erina Suzuki, Makoto Sasaki, Hiromi Kataoka. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice. Indian Journal of Gastroenterology 2020; 39(6): 565 doi: 10.1007/s12664-020-01092-1
|
| 49 |
S. Nikolaus, S. Schreiber. Anti-TNF-Biologika in der Therapie chronisch-entzündlicher Darmerkrankungen. Der Internist 2008; 49(8): 947 doi: 10.1007/s00108-008-2058-3
|
| 50 |
Anton Risto, Maie Abdalla, Pär Myrelid. Staging Pouch Surgery in Ulcerative Colitis in the Biological Era. Clinics in Colon and Rectal Surgery 2022; 35(01): 058 doi: 10.1055/s-0041-1740039
|
| 51 |
J. P. Gisbert, A. C. Marín, A. G. McNicholl, M. Chaparro. Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed. Alimentary Pharmacology & Therapeutics 2015; 41(7): 613 doi: 10.1111/apt.13083
|
| 52 |
Marisa Iborra, Javier Pérez-Gisbert, Marta Maia Bosca-Watts, Alicia López-García, Valle García-Sánchez, Antonio López-Sanromán, Esther Hinojosa, Lucía Márquez, Santiago García-López, María Chaparro, Montserrat Aceituno, Margalida Calafat, Jordi Guardiola, Blanca Belloc, Yolanda Ber, Luis Bujanda, Belén Beltrán, Cristina Rodríguez-Gutiérrez, Jesús Barrio, José Luis Cabriada, Montserrat Rivero, Raquel Camargo, Manuel van Domselaar, Albert Villoria, Hugo Salata Schuterman, David Hervás, Pilar Nos. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. Journal of Gastroenterology 2017; 52(7): 788 doi: 10.1007/s00535-016-1274-1
|
| 53 |
Waqqas Afif, Jonathan A. Leighton, Stephen B. Hanauer, Edward V. Loftus, William A. Faubion, Darrell S. Pardi, William J. Tremaine, Sunanda V. Kane, David H. Bruining, Russell D. Cohen, David T. Rubin, Karen A. Hanson, William J. Sandborn. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflammatory Bowel Diseases 2009; 15(9): 1302 doi: 10.1002/ibd.20924
|
| 54 |
A. Dignass, J.O. Lindsay, A. Sturm, A. Windsor, J.-F. Colombel, M. Allez, G. d’Haens, A. d’Hoore, G. Mantzanaris, G. Novacek, T. Öresland, W. Reinisch, M. Sans, E. Stange, S. Vermeire, S. Travis, G. van Assche. Segundo consenso europeo basado en evidencia sobre el diagnóstico y manejo de la colitis ulcerosa crónica idiopática. Parte 2: tratamiento actual (versión española). Revista de Gastroenterología de México 2015; 80(1): 32 doi: 10.1016/j.rgmx.2014.10.007
|
| 55 |
Simone Meijs, Tjibbe J. Gardenbroek, Mirjam A.G. Sprangers, Willem A. Bemelman, Christianne J. Buskens, Geert R.A.M. D’Haens, Mark Löwenberg. Health-related quality of life and disability in patients with ulcerative colitis and proctocolectomy with ileoanal pouch versus treatment with anti-TNF agents. Journal of Crohn's and Colitis 2014; 8(7): 686 doi: 10.1016/j.crohns.2013.12.011
|
| 56 |
Jeannie K. Lee, Derek H. Tang, Lea Mollon, Edward P. Armstrong. Cost-effectiveness of biological agents used in ulcerative colitis. Best Practice & Research Clinical Gastroenterology 2013; 27(6): 949 doi: 10.1016/j.bpg.2013.09.007
|
| 57 |
Takuya Yoshino, Makoto Sono, Shujiro Yazumi. Usefulness of sulfasalazine for patients with refractory-ulcerative colits. BMJ Open Gastroenterology 2016; 3(1): e000103 doi: 10.1136/bmjgast-2016-000103
|
| 58 |
Matthew W. Trinder, Ian C. Lawrance. Efficacy of adalimumab for the management of Inflammatory Bowel Disease in the Clinical Setting. Journal of Gastroenterology and Hepatology 2009; 24(7): 1252 doi: 10.1111/j.1440-1746.2009.05786.x
|
| 59 |
María José Casanova, María Chaparro, Miguel Mínguez, Elena Ricart, Carlos Taxonera, Santiago García-López, Jordi Guardiola, Antonio López-San Román, Eva Iglesias, Belén Beltrán, Beatriz Sicilia, María Isabel Vera, Joaquín Hinojosa, Sabino Riestra, Eugeni Domènech, Xavier Calvet, José Lázaro Pérez-Calle, María Dolores Martín-Arranz, Xavier Aldeguer, Montserrat Rivero, David Monfort, Jesús Barrio, María Esteve, Lucía Márquez, Rufo Lorente, Esther García-Planella, Luisa de Castro, Fernando Bermejo, Olga Merino, Antonio Rodríguez-Pérez, Pilar Martínez-Montiel, Manuel Van Domselaar, Guillermo Alcaín, Manuel Domínguez-Cajal, Carmen Muñoz, Fernando Gomollón, Luis Fernández-Salazar, Mariana Fe García-Sepulcre, Iago Rodríguez-Lago, Ana Gutiérrez, Federico Argüelles-Arias, Cristina Rodriguez, Gloria Esther Rodríguez, Luis Bujanda, Jordina Llaó, Pilar Varela, Laura Ramos, José María Huguet, Pedro Almela, Patricia Romero, Mercè Navarro-Llavat, Águeda Abad, Patricia Ramírez-de la Piscina, Alfredo J Lucendo, Eva Sesé, Rosa Eva Madrigal, Mara Charro, Antonio García-Herola, Ramón Pajares, Sam Khorrami, Javier P Gisbert. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. Inflammatory Bowel Diseases 2019; doi: 10.1093/ibd/izz192
|
| 60 |
A. OUSSALAH, C. LACLOTTE, J.‐B. CHEVAUX, M. BENSENANE, A. BABOURI, A.‐A. SERRE, T. BOUCEKKINE, X. ROBLIN, M.‐A. BIGARD, L. PEYRIN‐BIROULET. Long‐term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single‐centre experience. Alimentary Pharmacology & Therapeutics 2008; 28(8): 966 doi: 10.1111/j.1365-2036.2008.03811.x
|
| 61 |
Anna Viola, Daniela Pugliese, Sara Renna, Federica Furfaro, Flavio Caprioli, Renata D’Incà, Fabrizio Bossa, Stefano Mazza, Giuseppe Costantino, Massimo Claudio Fantini, Gionata Fiorino, Angela Alibrandi, Ambrogio Orlando, Alessandro Armuzzi, Walter Fries. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Digestive and Liver Disease 2019; 51(4): 510 doi: 10.1016/j.dld.2018.10.013
|
| 62 |
|
| 63 |
Feng Xie. The economics of adalimumab for ulcerative colitis. Expert Review of Pharmacoeconomics & Outcomes Research 2015; 15(3): 373 doi: 10.1586/14737167.2015.1031113
|
| 64 |
A. Noble, R. Baldassano, P. Mamula. Novel therapeutic options in the inflammatory bowel disease world. Digestive and Liver Disease 2008; 40(1): 22 doi: 10.1016/j.dld.2007.07.169
|
| 65 |
Jatinder P. Ahluwalia. Immunotherapy in Inflammatory Bowel Disease. Medical Clinics of North America 2012; 96(3): 525 doi: 10.1016/j.mcna.2012.04.009
|
| 66 |
Andrew B Grossman, Robert N Baldassano. Specific considerations in the treatment of pediatric inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2008; 2(1): 105 doi: 10.1586/17474124.2.1.105
|